Guardant Health, Inc. reported results for the quarter ended 2026 with revenue of $334.98M, up 44.3% from $232.09M a year earlier, while the company recorded a net loss of ($120.14M) and diluted loss per share of ($0.9).
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$334.98M$232.09M44.3% | Net income²($120.14M)($99.9M)(20.3%) | Diluted EPS³($0.9)($0.8)(12.5%) |
¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “loss per share, basic and diluted”.
Business Highlights
- Revenue growth was driven by higher oncology and screening volumes, with total revenue rising 44% year-over-year for the quarter and 46% year-to-date.
- Shield screening volumes increased materially, to about 66k tests in the quarter versus 16k in the prior-year quarter, expanding the screening mix.
- Test volumes scaled to roughly 104k oncology tests in the quarter, supported by laboratory capacity in California and New York.
- Commercial and clinical momentum included FDA approvals for Guardant360 Liquid CDx and Shield, expanded Medicare and major payer coverage, and ongoing clinical programs including SOLAR, SHIELD LUNG and ORACLE.
- Company investment increased in R&D and sales and marketing to support clinical studies and global expansion.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.